Advanced Biomed Statistics
Total Valuation
Advanced Biomed has a market cap or net worth of $4.92 million. The enterprise value is $5.62 million.
| Market Cap | 4.92M |
| Enterprise Value | 5.62M |
Important Dates
The next estimated earnings date is Wednesday, November 18, 2026, after market close.
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Advanced Biomed has 1.65 million shares outstanding. The number of shares has increased by 22.06% in one year.
| Current Share Class | 1.65M |
| Shares Outstanding | 1.65M |
| Shares Change (YoY) | +22.06% |
| Shares Change (QoQ) | +21.79% |
| Owned by Insiders (%) | 52.41% |
| Owned by Institutions (%) | 0.06% |
| Float | 677,083 |
Valuation Ratios
The trailing PE ratio is 0.56.
| PE Ratio | 0.56 |
| Forward PE | n/a |
| PS Ratio | 37.93 |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.83 |
| EV / Sales | 43.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.33, with a Debt / Equity ratio of 0.09.
| Current Ratio | 9.33 |
| Quick Ratio | 9.33 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -888.73 |
Financial Efficiency
Return on equity (ROE) is -79.49% and return on invested capital (ROIC) is -46.29%.
| Return on Equity (ROE) | -79.49% |
| Return on Assets (ROA) | -21.28% |
| Return on Invested Capital (ROIC) | -46.29% |
| Return on Capital Employed (ROCE) | -50.78% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $10,636 |
| Profits Per Employee | $556,423 |
| Employee Count | 12 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1,205 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.90% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -66.90% |
| 50-Day Moving Average | 6.75 |
| 200-Day Moving Average | 5.96 |
| Relative Strength Index (RSI) | 24.09 |
| Average Volume (20 Days) | 38,026 |
Short Selling Information
The latest short interest is 18,897, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 18,897 |
| Short Previous Month | 9,845 |
| Short % of Shares Out | 1.14% |
| Short % of Float | 2.79% |
| Short Ratio (days to cover) | 0.28 |
Income Statement
In the last 12 months, Advanced Biomed had revenue of $127,637 and earned $6.68 million in profits. Earnings per share was $5.33.
| Revenue | 127,637 |
| Gross Profit | 127,637 |
| Operating Income | -6.23M |
| Pretax Income | -6.26M |
| Net Income | 6.68M |
| EBITDA | -6.17M |
| EBIT | -6.23M |
| Earnings Per Share (EPS) | $5.33 |
Balance Sheet
The company has $385,535 in cash and $1.08 million in debt, with a net cash position of -$692,680 or -$0.42 per share.
| Cash & Cash Equivalents | 385,535 |
| Total Debt | 1.08M |
| Net Cash | -692,680 |
| Net Cash Per Share | -$0.42 |
| Equity (Book Value) | 12.28M |
| Book Value Per Share | 7.43 |
| Working Capital | 12.28M |
Cash Flow
| Operating Cash Flow | -1.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 59,281 |
| Net Borrowing | 1.08M |
| Free Cash Flow | -1.95M |
| FCF Per Share | -$1.18 |
Margins
Gross margin is 100.00%, with operating and profit margins of -4,883.80% and 5,231.30%.
| Gross Margin | 100.00% |
| Operating Margin | -4,883.80% |
| Pretax Margin | -4,906.48% |
| Profit Margin | 5,231.30% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Advanced Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.06% |
| Shareholder Yield | -22.06% |
| Earnings Yield | 178.86% |
| FCF Yield | -40.22% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 20, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Feb 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Advanced Biomed has an Altman Z-Score of 1.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 2 |